At Liptis, we believe it is very important for patients to understand their illness as well as their treatment options. Educated patients can be much more comfortable being active and informed participants in their own treatment. We are also committed to providing health care professionals with links to relevant online resources and educational opportunities.
As a prominent pharmaceutical company in the health care industry, Liptis brings to the world pharmaceutical and health care products that improve lives. We achieve this goal, in part, through education.
We believe in supporting physicians and other health care professionals in their effort to stay up to date with the constant improvements in medicine, through seminars and grants.
Liptis is proud to provide generous educational grants for various educational initiatives including grants to accredited sponsors for continuing education-medical (CME), pharmacy (CPE), or nursing (CNE).
Liptis's musculoskeletal research developed an important new therapies for patients with joint and bone disorders. Our products include treatments for osteoarthritis that help patients lead more active lives with less pain. In addition, Liptis has a strong presence in the treatment of osteoarthritis, our product Dorofen is one of the best sellers in its category. Liptis scientists are investigating novel treatments for bone and tissue repair, which may impact fracture healing and post-surgical recovery.
Our broad and expanding internal medicine franchise includes cardiovascular and gastrointestinal products. Liptis internal medicine researchers are exploring novel approaches to treat diabetes with our products Glybufen, Diofen, and Glucostat, treat depression with Modostat, treat vascular disorders with Cepress and treat liver diseases with Hepachol.
Liptis has a long history of pioneering developments in pharmaceuticals with leading products in the areas of women's health care, musculoskeletal disorder and cardiovascular therapy.
